MCID: ACT103
MIFTS: 55

Acute Lymphoblastic Leukemia, Childhood

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Lymphoblastic Leukemia, Childhood

MalaCards integrated aliases for Acute Lymphoblastic Leukemia, Childhood:

Name: Acute Lymphoblastic Leukemia, Childhood 39
Childhood Acute Lymphoblastic Leukemia 12 54 15
Childhood Acute Lymphocytic Leukemia 12 54 15
Pediatric Acute Lymphoblastic Leukemia 54
Lymphoblastic Leukemia Acute Childhood 56
Leukemia, Lymphocytic, Acute, L1 74
Childhood All 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0080144
NCIt 51 C3168
UMLS 74 C0023452

Summaries for Acute Lymphoblastic Leukemia, Childhood

NIH Rare Diseases : 54 Childhood acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow, and the most common type of cancer in children. In children with this condition, too many stem cells made by the bone marrow become lymphoblasts, B lymphocytes, or T lymphocytes. These cells do not function normally and have trouble fighting off infections. Signs and symptoms may include fever; easy bruising or bleeding; bone or joint pain; painless lumps in the neck, underarm, stomach, or groin; weakness; fatigue; and/or loss of appetite. Treatment depends on several factors and may include combination chemotherapy, targeted therapy, and/or stem cell transplant. On August 30 2017, Kymriah became the first gene therapy approved by the FDA. Kymriah is now an option for children and young adults up to 25 years old with B-Cell precursor ALL that has proven resistant to other treatments or has relapsed two or more times.

MalaCards based summary : Acute Lymphoblastic Leukemia, Childhood, also known as childhood acute lymphoblastic leukemia, is related to b-cell childhood acute lymphoblastic leukemia and childhood leukemia. An important gene associated with Acute Lymphoblastic Leukemia, Childhood is PAX8-AS1 (PAX8 Antisense RNA 1), and among its related pathways/superpathways are Pathways in cancer and One carbon pool by folate. The drugs Mercaptopurine and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 An acute lymphocytic leukemia occuring during childhood.

Related Diseases for Acute Lymphoblastic Leukemia, Childhood

Diseases related to Acute Lymphoblastic Leukemia, Childhood via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 b-cell childhood acute lymphoblastic leukemia 34.8 ETV6 RUNX1
2 childhood leukemia 30.2 ETV6 MTHFR RUNX1
3 central nervous system leukemia 30.1 MME RUNX1
4 leukemia, acute lymphoblastic 30.0 ABCB1 ETV6 FLT3 MME RUNX1 TPMT
5 mucositis 29.4 ABCB1 MTHFR TYMS
6 leukemia, acute myeloid 28.9 ABCB1 CDKN2B ETV6 FLT3 MME RUNX1
7 acute leukemia 28.6 ABCB1 ETV6 FLT3 GSTM1 MTHFR RUNX1
8 acute lymphocytic leukemia 27.5 ASNS CDKN2A CDKN2B ETV6 GSTM1 MME
9 t-cell childhood acute lymphocytic leukemia 12.4
10 leukemia 10.6
11 lymphocytic leukemia 10.6
12 osteonecrosis 10.3
13 methotrexate toxicity or dose selection 10.3 MTHFR SLC19A1
14 body mass index quantitative trait locus 1 10.3
15 hematopoietic stem cell transplantation 10.3
16 platelet disorder, familial, with associated myeloid malignancy 10.3 ETV6 RUNX1
17 upper thoracic spina bifida cystica 10.2 MTHFD1 MTHFR
18 cervicothoracic spina bifida cystica 10.2 MTHFD1 MTHFR
19 cervical spina bifida cystica 10.2 MTHFD1 MTHFR
20 lumbosacral spina bifida cystica 10.2 MTHFD1 MTHFR
21 retinoblastoma 10.2
22 anxiety 10.2
23 testicular disease 10.2
24 depression 10.2
25 thoracolumbosacral spina bifida cystica 10.2 MTHFD1 MTHFR
26 total spina bifida cystica 10.2 MTHFD1 MTHFR
27 tenosynovial giant cell tumor 10.2 CDKN2A CDKN2B
28 upper thoracic spina bifida aperta 10.2 MTHFD1 MTHFR
29 thoracolumbosacral spina bifida aperta 10.2 MTHFD1 MTHFR
30 lumbosacral spina bifida aperta 10.2 MTHFD1 MTHFR
31 cervical spina bifida aperta 10.2 MTHFD1 MTHFR
32 cervicothoracic spina bifida aperta 10.2 MTHFD1 MTHFR
33 total spina bifida aperta 10.2 MTHFD1 MTHFR
34 fallopian tube endometrioid adenocarcinoma 10.2 CDKN2A MME
35 scrotal carcinoma 10.2 CDKN2A CDKN2B
36 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.2 FLT3 RUNX1
37 diabetes mellitus, noninsulin-dependent 10.2
38 down syndrome 10.2
39 wilms tumor 1 10.2
40 lymphoma, hodgkin, classic 10.2
41 nijmegen breakage syndrome 10.2
42 aging 10.2
43 hepatitis 10.2
44 pancreatitis 10.2
45 atypical neurofibroma 10.1 CDKN2A CDKN2B
46 lymphoid leukemia 10.1 ETV6 FLT3
47 pediatric osteosarcoma 10.1 MTHFR SLC19A1
48 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.1 ETV6 FLT3 RUNX1
49 lymphoma, non-hodgkin, familial 10.1
50 diabetes mellitus 10.1

Graphical network of the top 20 diseases related to Acute Lymphoblastic Leukemia, Childhood:



Diseases related to Acute Lymphoblastic Leukemia, Childhood

Symptoms & Phenotypes for Acute Lymphoblastic Leukemia, Childhood

MGI Mouse Phenotypes related to Acute Lymphoblastic Leukemia, Childhood:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 ABCB1 ASNS CDKN2A CDKN2B ETV6 FLT3
2 homeostasis/metabolism MP:0005376 9.7 ABCB1 CDKN2A CDKN2B ETV6 FLT3 MME
3 no phenotypic analysis MP:0003012 9.17 ABCB1 CDKN2A CDKN2B ETV6 FLT3 MTHFR

Drugs & Therapeutics for Acute Lymphoblastic Leukemia, Childhood

Drugs for Acute Lymphoblastic Leukemia, Childhood (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 412)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
2
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
6
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
7
Idarubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58957-92-9 42890
8
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
9
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
10
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130167-69-0
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
12
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
13
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
14
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
18
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
19
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
20
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
21
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
22
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
23
Oprelvekin Approved, Investigational Phase 4 145941-26-0
24
Benzocaine Approved, Investigational Phase 4,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
25
tannic acid Approved Phase 4,Phase 2,Not Applicable 1401-55-4
26
Budesonide Approved Phase 4 51333-22-3 5281004 63006
27
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 46507594 772
28
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
30
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
31
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 1406-16-2
33
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
34
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
35
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
36
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
37
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 505)
# Name Status NCT ID Phase Drugs
1 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
2 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
3 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
4 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
5 Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients Unknown status NCT03043430 Phase 4 Ketamine 100 MG/ML;Midazolam 5 MG/ML
6 Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL Completed NCT02314273 Phase 4 rhIL-11
7 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
8 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
9 Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
10 Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge Recruiting NCT03369847 Phase 4 budesonide, beclomethasone
11 Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO Recruiting NCT03318393 Phase 4 Bivalirudin;Unfractionated heparin
12 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
13 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
14 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
15 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
16 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
17 Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia Unknown status NCT00003437 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;thioguanine;vincristine sulfate
18 Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia Unknown status NCT00002499 Phase 2, Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;dexamethasone;methotrexate;prednisone;vincristine sulfate
19 Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
20 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Unknown status NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus
21 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
22 Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant Unknown status NCT01817075 Phase 3 Chlorhexidine Gluconate
23 Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00002816 Phase 3 cytarabine;dexamethasone;etoposide;idarubicin;ifosfamide;leucovorin calcium;mesna;pegaspargase;therapeutic hydrocortisone;thioguanine;vincristine sulfate;Methotrexate
24 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
25 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase Completed NCT00819351 Phase 3 PEG Asparaginase at six weeks interval;PEG Asparaginase at two weeks interval
26 Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia Completed NCT00005585 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
27 Zometa Study in Pediatric Acute Lymphoblastic Leukemia Completed NCT01656512 Phase 3 zolendronic acid;calcium & vitamin D
28 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00103285 Phase 3 doxorubicin hydrochloride;cytarabine;dexamethasone;pegaspargase;methotrexate;leucovorin calcium;mercaptopurine;cyclophosphamide;thioguanine;vincristine sulfate
29 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia Completed NCT00022737 Phase 3 asparaginase;cyclophosphamide;cyclosporine;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;ifosfamide;imatinib mesylate;leucovorin calcium;mercaptopurine tablet;methotrexate;pegaspargase;vincristine sulfate
30 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine
31 A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors Completed NCT00186901 Phase 3 Calcium carbonate (Tums), vitamin D
32 Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia Completed NCT00005945 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
33 Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
34 Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia Completed NCT00015873 Phase 3 asparaginase;cytarabine;mercaptopurine;methotrexate;prednisolone;vincristine sulfate
35 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00005596 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
36 Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia Completed NCT00005603 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate
37 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed NCT00381680 Phase 3 vincristine sulfate;prednisone;doxorubicin hydrochloride;pegaspargase;cytarabine;methotrexate;dexamethasone;etoposide;cyclophosphamide;leucovorin calcium;asparaginase;mercaptopurine
38 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00002744 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisone;therapeutic hydrocortisone;thioguanine;vincristine sulfate
39 Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Completed NCT00002812 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;idarubicin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
40 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
41 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00720109 Phase 2, Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Vincristine Sulfate
42 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
43 Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed NCT00075725 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
44 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
45 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
46 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
47 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
48 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
49 Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
50 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus

Search NIH Clinical Center for Acute Lymphoblastic Leukemia, Childhood

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Acute Lymphoblastic Leukemia, Childhood:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Acute Lymphoblastic Leukemia, Childhood:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Acute Lymphoblastic Leukemia, Childhood

Anatomical Context for Acute Lymphoblastic Leukemia, Childhood

MalaCards organs/tissues related to Acute Lymphoblastic Leukemia, Childhood:

42
Bone, Bone Marrow, T Cells, Myeloid, B Cells, Kidney, Testes

Publications for Acute Lymphoblastic Leukemia, Childhood

Articles related to Acute Lymphoblastic Leukemia, Childhood:

(show top 50) (show all 2110)
# Title Authors Year
1
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. ( 30216644 )
2019
2
Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia. ( 30690723 )
2019
3
Type B Lactic Acidosis: A Rare Initial Presentation of Childhood Acute Lymphoblastic Leukemia. ( 30814800 )
2019
4
ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis. ( 31111395 )
2019
5
A Bayesian multivariate latent t-regression model for assessing the association between corticosteroid and cranial radiation exposures and cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia: a PETALE study. ( 31088361 )
2019
6
Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors. ( 31088516 )
2019
7
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. ( 31030032 )
2019
8
The relationship of child executive functions to parenting capacities in childhood acute lymphoblastic leukemia survivors. ( 31033172 )
2019
9
Cardiovascular dysfunction and vitamin D status in childhood acute lymphoblastic leukemia survivors. ( 31055782 )
2019
10
Is there a relationship between vitamin D nutritional status and metabolic syndrome in childhood acute lymphoblastic leukemia survivors? A PETALE study. ( 31060831 )
2019
11
Methylation of the promoter region of the MTRR gene in childhood acute lymphoblastic leukemia. ( 31002356 )
2019
12
Homozygous mutation in NUDT15 in childhood acute lymphoblastic leukemia with increased susceptibility to mercaptopurine toxicity: A case report. ( 31007757 )
2019
13
Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia. ( 30944321 )
2019
14
Survivorship care plan experiences among childhood acute lymphoblastic leukemia patients and their families. ( 30979365 )
2019
15
Identification of a single nucleotide polymorphism within CDH2 gene associated with bone morbidity in childhood acute lymphoblastic leukemia survivors. ( 30983502 )
2019
16
A cross-sectional follow-up study of physical morbidities, neurocognitive function, and attention problems in post-treatment childhood acute lymphoblastic leukemia survivors. ( 30913362 )
2019
17
Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in etiology. ( 30923090 )
2019
18
Race/ethnicity, socioeconomic position, and childhood acute lymphoblastic leukemia. ( 30924856 )
2019
19
MicroRNA as a diagnostic biomarker in childhood acute lymphoblastic leukemia; systematic review, meta-analysis and recommendations. ( 30878131 )
2019
20
Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment. ( 30832275 )
2019
21
Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ( 30835935 )
2019
22
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002. ( 30840197 )
2019
23
A genetic variant in miR-100 is a protective factor of childhood acute lymphoblastic leukemia. ( 30848099 )
2019
24
Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation. ( 30849662 )
2019
25
Is there etiologic heterogeneity between subtypes of childhood acute lymphoblastic leukemia? A review of variation in risk by subtype. ( 30770347 )
2019
26
Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors. ( 30778669 )
2019
27
Attenuating the abnormally high expression of AEBP1 suppresses the pathogenesis of childhood acute lymphoblastic leukemia via p53-dependent signaling pathway. ( 30779088 )
2019
28
Revisiting the complete blood count and clinical findings at diagnosis of childhood acute lymphoblastic leukemia: 10-year experience at a single center. ( 30793106 )
2019
29
Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia. ( 30684021 )
2019
30
Prevention of Long-term Adverse Health Outcomes With Cardiorespiratory Fitness and Physical Activity in Childhood Acute Lymphoblastic Leukemia Survivors. ( 30688830 )
2019
31
Evaluation of Insulin-mediated Regulation of AKT Signaling in Childhood Acute Lymphoblastic Leukemia. ( 30688831 )
2019
32
The role of adiponectin, LEPTIN, and ghrelin in the progress and prognosis of childhood acute lymphoblastic leukemia. ( 30696312 )
2019
33
NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia. ( 30719179 )
2019
34
Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM. ( 30655370 )
2019
35
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. ( 30664635 )
2019
36
Identification of novel lncRNAs involved in the pathogenesis of childhood acute lymphoblastic leukemia. ( 30675275 )
2019
37
ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on method's sensitivity. ( 30630977 )
2019
38
Dysregulation of miR-335-3p, targeted by NEAT1 and MALAT1 long non-coding RNAs, is associated with poor prognosis in childhood acute lymphoblastic leukemia. ( 30639603 )
2019
39
Minimal Residual Disease-guided Risk Restratification and Therapy Improves the Survival of Childhood Acute Lymphoblastic Leukemia: Experience From a Tertiary Children's Hospital in China. ( 30640823 )
2019
40
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. ( 30643249 )
2019
41
Prevalence and Risk Factors for Arterial Hypertension Development in Childhood Acute Lymphoblastic Leukemia Survivors. ( 30475300 )
2019
42
Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. ( 30510082 )
2019
43
Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing. ( 30446805 )
2019
44
Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors ( 30398158 )
2019
45
Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy. ( 30324220 )
2019
46
Brain Activity Associated With Attention Deficits Following Chemotherapy for Childhood Acute Lymphoblastic Leukemia. ( 29790971 )
2019
47
Quantitative Ultrasound of Proximal Phalanxes in Childhood Acute Lymphoblastic Leukemia Survivors. ( 29620678 )
2019
48
Coagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase. ( 29406239 )
2019
49
Vitamin D nutritional status and bone turnover markers in childhood acute lymphoblastic leukemia survivors: A PETALE study. ( 29503055 )
2019
50
Living on a farm, contact with farm animals and pets, and childhood acute lymphoblastic leukemia: pooled and meta-analyses from the Childhood Leukemia International Consortium. ( 29663688 )
2018

Variations for Acute Lymphoblastic Leukemia, Childhood

Copy number variations for Acute Lymphoblastic Leukemia, Childhood from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 250737 9 21967751 21994490 Deletion CDKN2A pediatric acute lymphoblastic leukemia

Expression for Acute Lymphoblastic Leukemia, Childhood

Search GEO for disease gene expression data for Acute Lymphoblastic Leukemia, Childhood.

Pathways for Acute Lymphoblastic Leukemia, Childhood

GO Terms for Acute Lymphoblastic Leukemia, Childhood

Biological processes related to Acute Lymphoblastic Leukemia, Childhood according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 one-carbon metabolic process GO:0006730 9.48 MTHFD1 MTHFR
2 negative regulation of phosphorylation GO:0042326 9.46 CDKN2A CDKN2B
3 hematopoietic stem cell proliferation GO:0071425 9.43 ETV6 RUNX1
4 replicative senescence GO:0090399 9.4 CDKN2A MME
5 methionine biosynthetic process GO:0009086 9.37 MTHFD1 MTHFR
6 tetrahydrofolate metabolic process GO:0046653 9.32 MTHFR TYMS
7 response to folic acid GO:0051593 9.26 MTHFR TYMS
8 methionine metabolic process GO:0006555 9.16 MTHFD1 MTHFR
9 folic acid metabolic process GO:0046655 9.13 MTHFD1 MTHFR SLC19A1
10 tetrahydrofolate interconversion GO:0035999 8.8 MTHFD1 MTHFR TYMS

Molecular functions related to Acute Lymphoblastic Leukemia, Childhood according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cofactor binding GO:0048037 9.16 ASNS TYMS
2 folic acid binding GO:0005542 8.96 SLC19A1 TYMS
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN2A CDKN2B

Sources for Acute Lymphoblastic Leukemia, Childhood

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....